Get the Stockscreener App
6.90
4.56%
-0.33
After Hours:
6.89
-0.01
-0.14%
Solid Biosciences Inc stock is traded at $6.90, with a volume of 1.42M.
It is down -4.56% in the last 24 hours and down -7.88% over the past month.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
See More
Previous Close:
$7.23
Open:
$7.36
24h Volume:
1.42M
Relative Volume:
1.10
Market Cap:
$679.05M
Revenue:
$14.79M
Net Income/Loss:
$-174.33M
P/E Ratio:
-3.4126
EPS:
-2.0219
Net Cash Flow:
$-157.44M
1W Performance:
-7.38%
1M Performance:
-7.88%
6M Performance:
+75.57%
1Y Performance:
+63.12%
1-Day Range:
$6.7616
$7.48
1-Week Range:
$6.7616
$7.535
52-Week Range:
$2.41
$8.8661
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.90 | 711.53M | 14.79M | -174.33M | -157.44M | -2.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Guggenheim | Buy |
| Dec-04-25 | Initiated | Needham | Buy |
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan
One new Solid Biosciences employee gets 8,070 stock units - Stock Titan
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Solid Biosciences receives EU orphan drug status for SGT-003 - Investing.com UK
Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG - GuruFocus
Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
EU grants orphan status to Solid’s Duchenne gene therapy candidate - Stock Titan
Solid Biosciences Announces Receipt of European Commission - GlobeNewswire
Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
BlackRock (NASDAQ: SLDB) holds 4.7% of Solid Biosciences, 4.58M shares - Stock Titan
Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research - Traders Union
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences Inc. commits to industry and advocacy collaboration on Duchenne - Traders Union
Solid Biosciences (NASDAQ: SLDB) seeks approval to double authorized shares at 2026 meeting - Stock Titan
Solid Biosciences (SLDB) COO earns 79,341 RSUs on performance milestone - Stock Titan
Solid Biosciences (NASDAQ: SLDB) CMO awarded 58,847 RSUs on milestone - Stock Titan
Solid Biosciences (SLDB) CEO earns 169,401 RSUs tied to PSUs - Stock Titan
Solid Biosciences (SLDB) CTO earns 54,925 RSUs on performance milestone - Stock Titan
Solid Biosciences (SLDB) CFO awarded 56,647 RSUs after performance milestone - Stock Titan
Solid Biosciences (NASDAQ: SLDB) awards 54,925 performance-based RSUs - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials - Traders Union
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Solid Biosciences Inc. to present new targeting strategies in gene therapy - Traders Union
Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Who Backs Solid Biosciences (SLDB) Stock (Modest Uptick) 2026-04-18Index Investing - Cổng thông tin điện tử Tỉnh Sơn La
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB) - The Globe and Mail
Needham Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month HighHere's What Happened - MarketBeat
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Dow Update: Is Solid Biosciences Inc part of any ETF2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9%Here's Why - MarketBeat
Sell Signal: Can Solid Biosciences Inc maintain its current growth rate2026 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn
Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com Australia
Solid Biosciences Inc. Files Form 8-K with SEC Detailing Company Information and No Amendments as of April 10, 2026 - Minichart
Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen - MarketBeat
Solid Biosciences reclassifies board member Ilan Ganot to Class I director By Investing.com - Investing.com Australia
Solid Biosciences Adjusts Board Classes in Governance Move - TipRanks
Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan
Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan
Activity Recap: Can Solid Biosciences Inc maintain its current growth rateOil Prices & Long-Term Safe Return Strategies - baoquankhu1.vn
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):